Search

Displaying results 951 - 960 of 3020 in total
  1. Drug

    Etuvetidigene Autotemcel

    go.drugbank.com/drugs/DB17593
    ApprovedInvestigational

    Etuvetidigene autotemcel is an autologous gene therapy which includes hematopoietic stem cells (HSCs) that have been genetically modified ex vivo. … [L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients.

  2. Drug

    Triclocarban

    go.drugbank.com/drugs/DB11155
    Approved

    In 2017, the US FDA prohibited the marketing of over-the-counter (OTC) consumer antiseptic wash products containing triclocarban due to negative health effects such as bacterial resistance or hormonal

  3. Drug

    Dyclonine

    go.drugbank.com/drugs/DB00645
    ApprovedInvestigational

    Dyclonine is an oral anaesthetic found in Sucrets, an over the counter throat lozenge. It may also be found in some Cepacol sore throat spray products.

  4. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    small cell lung cancer (ES-SCLC). … It was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma.

  5. Drug

    L-Glutamine

    go.drugbank.com/drugs/DB00130
    ApprovedInvestigationalNutraceutical

    An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.

  6. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022.

  7. Drug

    Yellow fever vaccine

    go.drugbank.com/drugs/DB10805
    ApprovedInvestigational

    10 days after vaccination; in two separate clinical trials of Yellow Fever Vaccine, 90% of subjects seroconverted within 10 days after vaccination, and 100% of subjects seroconverted within 14 days [FDA … It is composed of two live, attenuated strains of yellow fever virus, 17D-204 and 17DD, which have been shown to elicit an immune response identical to that induced by wild-type infection [FDA Label, A32118

  8. Drug

    Lenalidomide

    go.drugbank.com/drugs/DB00480
    ApprovedInvestigational

    [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal

  9. Drug

    Etidronic acid

    go.drugbank.com/drugs/DB01077
    ApprovedInvestigational

    [A1923] Etidronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate [zoledronic acid], [ibandronic acid], [minodronic acid], and [risedronic acid] … [A203111] Etidronic acid was granted FDA approval on 1 September 1977.[L13901]

  10. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week. … It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™.